In addition, tissues of several other cancers, including invasive breast carcinomas with the BRCA mutation, glioblastoma multiforme and pancreatic adenocarcinoma, also expressed high levels of PRRX1 and TOP2A (Fig. 1a and Fig. S7A), indicating that functional inhibition of the PRRX1-TOP2A interaction might provide an alternative strategy to direct inhibition of TOP2A, which has severe side effects in vivo [45], for the therapy of a broad spectrum of human cancers. This evidence concerns the gene TOP2A and cancer.